ALZN Stock Summary and Trading Ideas (Alzamend Neuro | NASDAQ:ALZN)

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Alzamend Neuro trades on the NASDAQ stock market under the symbol ALZN.

As of January 28, 2025, ALZN stock price declined to $1.12 with 62,796 million shares trading.

ALZN has a beta of 1.37, meaning it tends to be more sensitive to market movements. ALZN has a correlation of 0.03 to the broad based SPY ETF.

ALZN has a market cap of $6.08 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ALZN traded as high as $239.25 and as low as $1.06.

The top ETF exchange traded funds that ALZN belongs to (by Net Assets): VXF.

ALZN has underperformed the market in the last year with a price return of -86.2% while the SPY ETF gained +25.6%. ALZN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.4% and -2.6%, respectively, while the SPY returned +4.8% and +4.1%, respectively.

ALZN support price is $1.09 and resistance is $1.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALZN shares will trade within this expected range on the day.